

RECONCILIATION FROM REPORTED REVENUE TO UNDERLYING REVENUE

(BN YEN)	FY2018 ^{*1} Q3 YTD	FY2019 Q3 YTD	vs. PY	
Revenue	1,380.0	2,519.5	+1,139.5	+82.6%
Shire Revenue	1,291.5	-		
Pro-forma Revenue	2,671.5	2,519.5	-152.1	-5.7%
FX effects ^{*2}				+3.3pp
Divestitures ^{*3}				+1.2pp
Techpool & Multilab				+0.3pp
XIIDRA & TACHOSIL				+1.0pp
Others				-0.1pp
Underlying Revenue Growth				-1.2%

^{*1} FY2018 Q3 YTD revenue is a pro-forma which adds Legacy Shire's 9 month (April - December 2018) revenue previously reported under US GAAP and conformed to IFRS without material differences, excluding Legacy Shire's oncology business, which was sold in August 2018, and converted to JPY using FY2018 actual rate for the period.

^{*2} FX adjustment applies constant FY2018 actual full year average rate to both years (1USD=111 yen, 1EUR=129 yen).

^{*3} Major adjustments are the exclusion of FY2018 Q3 YTD revenue of former subsidiaries, Guangdong Techpool Bio-Pharma Co., Ltd., and Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda., both divested in FY2018, and FY2018 Q3 YTD and FY2019 Q3 YTD revenue of XIIDRA which was divested in July 2019 and TACHOSIL as Takeda agreed in May 2019 to divest this product, with completion of divestiture expected to occur within FY2019.

REPORTED AND UNDERLYING GROWTH OF LEGACY SHIRE PRODUCT/THERAPEUTIC AREA SALES

(BN YEN)	FY2018 YTD		FY2019 YTD		Underlying Growth
	Reported ^{*1}	FX	Reported	FX	
GI	496.9	+1.4	533.2	-14.1	+10.5%
Legacy Shire	104.0	+0.3	90.0	-2.2	-11.0%
LIALDA	36.6	+0.1	18.2	-0.7	-48.1%
GATTEX / REVESTIVE	39.2	+0.1	46.9	-1.0	+22.6%
Rare Diseases	572.2	+1.4	485.5	-23.8	-10.8%
Rare Metabolic	148.4	+0.5	132.3	-10.2	-3.6%
NATPARA	20.5	+0.0	13.0	-0.2	-35.5%
Rare Hematology	314.8	+0.7	259.2	-10.8	-14.0%
ADVATE	156.5	+0.8	123.1	-5.5	-17.4%
ADYNOVATE	44.0	+0.1	44.8	-1.0	+4.4%
FEIBA	54.4	-0.3	39.6	-2.2	-23.5%
Hereditary Angioedema	109.0	+0.2	94.0	-2.8	-11.0%
FIRAZYR	62.9	+0.2	22.7	-1.2	-61.8%
TAKHZYRO	6.9	+0.0	48.8	-1.0	+622.2%
CINRYZE	32.9	-0.1	18.9	-0.5	-41.1%
PDT Immunology	290.9	+0.9	296.6	-8.3	+5.1%
Legacy Shire	278.4	+0.9	283.5	-8.3	+5.1%
Immunoglobulin	222.4	+0.9	225.4	-5.8	+4.4%
Legacy Shire	213.3	+0.9	215.6	-5.8	+4.3%
Albumin	47.1	(0.1)	49.7	-2.1	+9.8%
Legacy Shire	45.9	(0.1)	48.5	-2.1	+10.0%
Others	21.4	+0.1	21.5	-0.4	+2.6%
Legacy Shire	19.3	+0.1	19.4	-0.4	+2.8%
Neuroscience	323.4	+1.1	330.5	-6.7	+4.6%
Legacy Shire	249.7	+1.0	248.1	-5.8	+2.1%
VYVANSE	197.4	+0.7	206.8	-4.5	+7.4%
ADDERALL XR	28.7	+0.1	15.0	-0.2	-46.9%

^{*1} Pro-forma based Legacy Shire's product sales and therapeutic area sales include Legacy Shire's products. FY2018 Q3 YTD revenue is a pro-forma which adds Legacy Shire's 9 month (April - December 2018) revenue previously reported under US GAAP and conformed to IFRS without material differences, excluding Legacy Shire's oncology business, which was sold in August 2018, and converted to JPY using FY2018 actual rate for the period.